REPLAY | FebriDx US Launch Update
12 June 2026
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales, Tommy Hall and PHASE Scientific's VP of Commercial Operations, Bob Gergen recently discussed how the Company strengthening its market footprint since receiving FDA CLIA waiver clearance for FebriDx in March 2026.
